NASDAQ: ANEB
Anebulo Pharmaceuticals Inc Stock Ownership - Who owns Anebulo Pharmaceuticals?

Insider buying vs selling

Have Anebulo Pharmaceuticals Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Aron R. EnglishDirector2024-12-2310,101,010$0.99
$10.00MBuy

1 of 1

ANEB insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ANEB insiders and whales buy or sell their stock.

ANEB Shareholders

What type of owners hold Anebulo Pharmaceuticals Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Aron R. English48.98%20,121,828$45.48MInsider
22nw LP37.65%15,467,300$34.96MInstitution
Joseph F. Lawler29.21%12,000,000$27.12MInsider
Nantahala Capital Management LLC7.39%3,036,325$6.86MInstitution
Mangrove Partners IM LLC6.15%2,525,252$5.71MInstitution
Morgan Stanley0.97%399,404$902.65kInstitution
Vanguard Group Inc0.75%306,540$692.78kInstitution
Geode Capital Management LLC0.42%174,108$393.48kInstitution
Ikarian Capital LLC0.38%157,720$356.45kInstitution
Renaissance Technologies LLC0.07%28,500$64.41kInstitution

1 of 3

ANEB vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ANEB40.89%59.11%Net Buying
HYFT8.91%0.00%
ADAG9.71%0.00%
PRLD43.21%52.21%Net BuyingNet Selling
ADVM25.41%74.59%Net SellingNet Selling

Anebulo Pharmaceuticals Stock Ownership FAQ

Who owns Anebulo Pharmaceuticals?

Anebulo Pharmaceuticals (NASDAQ: ANEB) is owned by 54.08% institutional shareholders, 78.18% Anebulo Pharmaceuticals insiders, and 0.00% retail investors. Aron R. English is the largest individual Anebulo Pharmaceuticals shareholder, owning 20.12M shares representing 48.98% of the company. Aron R. English's Anebulo Pharmaceuticals shares are currently valued at $45.48M.

If you're new to stock investing, here's how to buy Anebulo Pharmaceuticals stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.